Keywords: Merck & Co, Ampakine compounds, Returns rights, Cortex, BioRelix, Antibacterials

Merck & Co returns Ampakine compounds rights to Cortex; signs antibacterials deal with BioRelix

Article | 05 October 2010

Print This

In a further re-evaluation of its research priorities, US drugs giant Merck & Co (NYSE: MRK) has returned worldwide rights ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in